SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

About this update from Caprock Mining Corp

[{"type":"text","content":"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics\n\n\n\n\n Faruqi & Faruqi, LLP Securities Litigation Partner\n \n\n\n James (Josh) Wilson\n \n\n\n Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options\n \n\n\n\n If you purchased or acquired securities in\n \n\n\n Capricor\n \n\n\n between October 9, 2024 and July 10, 2025\n \n and would like to discuss your legal rights, call Faruqi & Faruqi partner\n \n Josh Wilson directly\n \n at\n \n 877-247-4292\n \n or\n \n 212-983-9330 (Ext. 1310)\n \n .\n \n\n\n\n [You may also click here for additional information]\n \n\n\n\n\n\n\n\n\n NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) --\n \n Faruqi & Faruqi, LLP\n \n , a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the\n \n September 15, 2025 deadline\n \n to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.\n \n\n Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See\n \n www.faruqilaw.com\n \n .\n \n\n As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.\n \n\n On July 11, 2025, Capricor issued a press relea...

More updates from Caprock Mining Corp